Literature DB >> 8447289

Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. High prevalence in ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis.

S Hardarson1, D R Labrecque, F A Mitros, G A Neil, J A Goeken.   

Abstract

The prevalence of antineutrophil cytoplasmic antibodies was evaluated in patients with ulcerative colitis, primary sclerosing cholangitis, and various other gastrointestinal and hepatobiliary diseases to define the sensitivity and specificity of the test. The presence of antineutrophil cytoplasmic antibodies was detected in alcohol-fixed cytospin preparations of peripheral blood neutrophils with an indirect immunofluorescence technique. A perinuclear staining pattern was considered positive. Thirty-six of 50 patients (72%) with ulcerative colitis and/or primary sclerosing cholangitis had positive results. Twenty-two of 210 patients (10%) in the control group had positive findings, including a significant proportion of patients with autoimmune hepatitis (50%) and non-A, non-B and non-C hepatitis (27%). This test for antineutrophil cytoplasmic antibodies has a sensitivity of 72% and specificity of 90% for either ulcerative colitis or primary sclerosing cholangitis. It may be useful in the differential diagnosis of Crohn's disease and ulcerative colitis and in the early diagnosis of ulcerative colitis. It also may be employed to distinguish primary biliary cirrhosis from primary sclerosing cholangitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8447289     DOI: 10.1093/ajcp/99.3.277

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  19 in total

1.  IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis.

Authors:  C Schwarze; B Terjung; P Lilienweiss; U Beuers; V Herzog; T Sauerbruch; U Spengler
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

Review 2.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

3.  Comparative evaluation of unfixed and fixed human neutrophils for determination of antineutrophil cytoplasmic antibodies by indirect immunofluorescence.

Authors:  P Yang
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

Review 4.  Pulmonary manifestations of inflammatory bowel disease.

Authors:  Xiao-Qing Ji; Li-Xia Wang; De-Gan Lu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

5.  Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies.

Authors:  P Billing; S Tahir; B Calfin; G Gagne; L Cobb; S Targan; A Vidrich
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

Review 6.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

7.  Demonstration of autoantibodies to recombinant human sulphite oxidase in patients with chronic liver disorders and analysis of their clinical relevance.

Authors:  B Preuss; C Berg; F Altenberend; M Gregor; S Stevanovic; R Klein
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

8.  High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis.

Authors:  P R Fleshner; E A Vasiliauskas; L Y Kam; N E Fleshner; J Gaiennie; M T Abreu-Martin; S R Targan
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 9.  Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"?

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

10.  Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis.

Authors:  A Vidrich; J Lee; E James; L Cobb; S Targan
Journal:  J Clin Immunol       Date:  1995-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.